Platinum-based chemotherapy drugs such as cisplatin and carboplatin leave lasting genetic scars on healthy tissues, artificially aging treated children’s organs and raising the risk of secondary cancers later in life, according to a study published in Science. Researchers from King’s College Hospital and the Francis Crick Institute analyzed liver tissue from young patients and found that the DNA-damaging treatments create extensive mutational signatures, transforming the molecular profile of pediatric organs to resemble those of adults.
How Platinum Chemotherapy Alters Healthy DNA in Children
Platinum-based medications serve as a vital lifeline for pediatric oncology patients, dramatically improving survival rates for aggressive conditions like hepatoblastoma, a rare pediatric liver cancer. According to reporting from STAT News, these regimens pushed five-year survival rates for localized hepatoblastoma tumors from 20% to over 80%. However, the core mechanism that makes these drugs effective against malignant growths—damaging cellular DNA—also impacts surrounding healthy tissue.
Researchers used advanced DNA sequencing technologies, including NanoSeq, to examine liver biopsies from children treated for hepatoblastoma. According to Foad Rouhani, a senior author on the study and a professor at King’s College in London, investigators discovered that exposure to platinum agents triggers an average of 2,200 mutations per liver sample. These genetic changes are not random; they exhibit distinct mutational signatures directly linked to platinum exposure.
Did you know? Mutation loads in the liver increase proportionally with treatment intensity. Children who received only cisplatin showed fewer mutations compared to patients who received a combination of both cisplatin and carboplatin, according to data cited by STAT News.
The study revealed that these drug-induced alterations effectively age pediatric liver cells. When comparing the mutation volume in treated pediatric tissue to normal adult baselines, researchers found that the chemotherapy damage had aged the children’s livers to a biological state matching that of an adult.
Broader Implications for Cancer Survivors and Long-Term Health
The discovery sheds light on long-standing clinical observations where pediatric cancer survivors develop secondary medical complications, including liver diseases or new malignancies, decades after initial remission. Rouhani noted during a discussion with Chris Smith that while clinicians always knew chemotherapy affected background tissue, the sheer extent of the genetic damage remained invisible prior to modern high-resolution sequencing.
Interestingly, the mutation burden was significantly higher in liver cells than in blood samples from the same patients, even though chemotherapy circulates systemically. According to Rouhani, this disparity suggests that liver cells either metabolize platinum compounds differently or handle DNA repair through distinct cellular pathways.
In a perspective article published alongside the study, Baylor College of Medicine professors Sanjeev Vasudevan and Donald Williams Parsons emphasized that the findings supply strong evidence for conducting extended survivorship studies, monitoring pediatric cancer patients well beyond their third decade of life.
Future Directions in Pediatric Oncology and Safer Therapeutics
Rather than sounding an alarm, study authors stress that the findings offer a clear path forward for clinical monitoring. Establishing that this specific tissue damage occurs allows physicians to track high-risk patients more closely and catch potential liver pathologies or secondary tumors at an earlier, more manageable stage.
Beyond enhanced surveillance, the research could redirect drug development efforts in oncology. Rouhani pointed out that understanding the exact molecular mechanisms of background tissue damage opens the door to designing next-generation chemotherapies capable of eradicating cancer cells while leaving healthy organs largely untouched.
Frequently Asked Questions
What causes the genetic scars found in pediatric cancer survivors?
Platinum-based chemotherapy drugs, such as cisplatin and carboplatin, target cancer by damaging DNA. The study published in Science shows these same drugs leave distinct mutational signatures in healthy background tissues.
How much does platinum chemotherapy age a child’s liver?
According to researchers at King’s College Hospital and the Francis Crick Institute, the mutation load found in treated liver tissue matches the genetic damage typically accumulated in an adult liver, effectively aging the organ to a biological state similar to that of an adult.
Does this accelerated aging happen in adults as well?
While the study specifically focused on pediatric hepatoblastoma patients, researchers note that it follows logically that DNA-damaging chemotherapy agents would induce similar mutational burdens in adult tissues.
Do these mutations mean cancer will definitely return?
No. According to study authors, the presence of cancer-associated genes and metabolic changes indicates an elevated biological risk or potential for future problems, but it does not guarantee that the healthy cells will become malignant.
What are your thoughts on balancing lifesaving cancer treatments with long-term organ health? Join the discussion below and subscribe to our newsletter for the latest updates in medical research.
Related reading